At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET
Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 million, following a clinical milestone in its ronde-cel PiNACLE trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer to lead financial strategy amid this capital raise.
- Lyell closed an additional $50 million tranche of a $100 million private placement after achieving a clinical milestone in the ronde-cel PiNACLE trial.
- Total gross proceeds from the private placement are now $100 million, priced at $25.61 per share.
- Cash runway is expected to extend into Q2 2027.
- Smital Shah was appointed Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biopharma finance and strategy experience.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access